News

Discover the latest news stories, blog posts and publications from Cobra's expert team

Home / News

or

Posts about

DNA

INTERVIEW: Ola Tuvesson discusses COVID-19 vaccine production with SVT

DNA, vaccine, COVID-19, interview

Företag i Matfors ska tillverka supermodernt coronavaccin

Links & Downloads: Cobra Articles

DNA, gene, plasmid, bacteria, biologics, process, peer reviewed, CMO, vaccine, therapy, cell, development, articles, biopharmaceuticals, microbioreactor, single-use

Peer Reviewed Publications A selection of links and downloadable magazine articles

BLOG: Cobra Granted MHRA Licence for Commercial Supply of a Client’s Product

Viral Vectors, DNA, blog, commercial supply, MHRA

Cobra Biologics has been granted a Commercial Licence from the UK Medicines and Healthcare products Regulatory Agency (MHRA), to manufacture and distribute a product for commercial supply.

BLOG: COVID-19 Vaccine Hopes and Hurdles

Viral Vectors, DNA, blog, vaccine, Coronavirus, COVID-19

Cobra has been fortunate to be given the opportunity to work with two novel vaccine candidates against COVID-19, utilising the company’s knowledge and experience in the production... Cobra Biologics has been fortunate to be given the opportunity to work with two novel vaccine candidates against COVID-19, utilising the company’s knowledge and experience in the production of plasmid DNA and viral vaccines. This blog aims to give a short introduction into the different types of vaccines that are in use, including the platform approaches relating to these two candidates and to highlight some of the potential manufacturing and

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

DNA, vaccine, Coronavirus, COVID-19, clinical trials

OPENCORONA consortium awarded €3million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak (Svensk version nedan)

INTERVIEW: Cobra Matfors to manufacture COVID-19 vaccine

DNA, vaccine, COVID-19, interview

Företag i Matfors ska tillverka supermodernt coronavaccin

Cobra Biologics and Symbiosis Complete £4.8m Viral Vector Supply Chain Collaboration

Viral Vectors, DNA, business, Advanced Therapy Medicinal Product, Innovate UK, ATMP, Manufacturing, immunotherapy, Cobra Biologics, Innovate, CDMO, Symbiosis

Developing world-leading capabilities in drug substance and drug product viral vector production for gene and immunotherapy.

Cobra Biologics and the University of Leeds Collaborate in BioProNET Funded Project

DNA, gene, viral, therapy, vector

£100K grant will fund proof-of-concept studies to optimise bioprocessing of gene therapy vectors using hydrodynamic fluid flow fields. Keele and Leeds, UK, 30th October 2018: Cobra Biologics and the University of Leeds have been awarded £100,000 to investigate the effects of hydrodynamic force on the structure and biological integrity of viral vector gene therapy products. This proof-of-concept grant is funded by the Biotechnology and Biological Sciences Research Council (BBSRC) Networks in Industrial Biotechnology and Bioenergy (NIBB) BioProNET, a network that brings together

Cobra Biologics, GE Healthcare and Centre for Process Innovation Collaborate to Advance Gene Therapy

Viral Vectors, DNA, CPI, Cobra Biologics, Innovate, Centre for Process Innovation, GE Healthcare, adeno-associated virus, Puridify

Innovate UK funded project supports development of scalable, cost effective production of regenerative medicines

Links & Downloads: Peer Reviewed Publications

DNA, gene, plasmid, bacteria, biologics, process, peer reviewed, CMO, vaccine, therapy, cell, development, articles, biopharmaceuticals, microbioreactor, single-use

A selection of downloadable journal articles and book chapters from the team at Cobra

Cobra Biologics Awarded £2.6m ($3.4m USD) from Innovate UK

DNA, Gene Therapy, Advanced Therapy Medicinal Product, Innovate UK, viral vector, Manufacturing, expansion, investment, jobs, grant, competition, Industrial Strategy, Immune-oncology, UK medicine

Capital infrastructure investment to embed and secure clinical and commercial viral vector manufacturing capability within the UK Capital infrastructure investment to embed and secure clinical and commercial viral vector manufacturing capability within the UK Award made as part of UK’s Innovation Agency’s Industrial Strategy boost for UK medicines with £70m of funding to help develop new treatments Cobra Biologics, an international CDMO of biologics and pharmaceuticals, announced that it has been awarded £2.6 million ($3.4 million) capital infrastructure investment by

1 2